Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Relapsed or Refractory Solid Tumors
Latest Information Update: 06 Apr 2022
Price :
$35 *
At a glance
- Drugs Irinotecan (Primary) ; Sorafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 31 Jan 2012 New trial record